An evaluation of gemcitabines differential radiosensitising effect in related bladder cancer cell lines

The aim of this study was to establish the radiosensitising properties of gemcitabine in a pair of related bladder tumour cell lines with differential radiosensitivity. The radioresistant bladder tumour cell line MGH-U1 and its radiosensitive mutant clone, S40b (both p53 mutant), had SF(2) values (s...

Descripción completa

Detalles Bibliográficos
Autores principales: Sangar, V K, Cowan, R, Margison, G P, Hendry, J H, Clarke, N W
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409540/
https://www.ncbi.nlm.nih.gov/pubmed/14735206
http://dx.doi.org/10.1038/sj.bjc.6601538
_version_ 1782155791786049536
author Sangar, V K
Cowan, R
Margison, G P
Hendry, J H
Clarke, N W
author_facet Sangar, V K
Cowan, R
Margison, G P
Hendry, J H
Clarke, N W
author_sort Sangar, V K
collection PubMed
description The aim of this study was to establish the radiosensitising properties of gemcitabine in a pair of related bladder tumour cell lines with differential radiosensitivity. The radioresistant bladder tumour cell line MGH-U1 and its radiosensitive mutant clone, S40b (both p53 mutant), had SF(2) values (surviving fraction at 2 Gy) of 0.98 and 0.64, respectively (P<0.001). Colony-forming assays showed that at 0.01 μM gemcitabine radiosensitisation occurred only in the S40b cell line (dose-modifying factor (DMF)=1.4). At 0.3 μM (killing 50% of cells), both cell lines were radiosensitised; DMF=2.25 and 1.2 for MGH-U1 and S40b, respectively. These data suggest that gemcitabine is an effective radiosensitiser in bladder cancer cell lines, with greater sensitisation in the radioresistant parental line–a feature that should be useful in a clinical setting.
format Text
id pubmed-2409540
institution National Center for Biotechnology Information
language English
publishDate 2004
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-24095402009-09-10 An evaluation of gemcitabines differential radiosensitising effect in related bladder cancer cell lines Sangar, V K Cowan, R Margison, G P Hendry, J H Clarke, N W Br J Cancer Experimental Therapeutics The aim of this study was to establish the radiosensitising properties of gemcitabine in a pair of related bladder tumour cell lines with differential radiosensitivity. The radioresistant bladder tumour cell line MGH-U1 and its radiosensitive mutant clone, S40b (both p53 mutant), had SF(2) values (surviving fraction at 2 Gy) of 0.98 and 0.64, respectively (P<0.001). Colony-forming assays showed that at 0.01 μM gemcitabine radiosensitisation occurred only in the S40b cell line (dose-modifying factor (DMF)=1.4). At 0.3 μM (killing 50% of cells), both cell lines were radiosensitised; DMF=2.25 and 1.2 for MGH-U1 and S40b, respectively. These data suggest that gemcitabine is an effective radiosensitiser in bladder cancer cell lines, with greater sensitisation in the radioresistant parental line–a feature that should be useful in a clinical setting. Nature Publishing Group 2004-01-26 2004-01-20 /pmc/articles/PMC2409540/ /pubmed/14735206 http://dx.doi.org/10.1038/sj.bjc.6601538 Text en Copyright © 2004 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Experimental Therapeutics
Sangar, V K
Cowan, R
Margison, G P
Hendry, J H
Clarke, N W
An evaluation of gemcitabines differential radiosensitising effect in related bladder cancer cell lines
title An evaluation of gemcitabines differential radiosensitising effect in related bladder cancer cell lines
title_full An evaluation of gemcitabines differential radiosensitising effect in related bladder cancer cell lines
title_fullStr An evaluation of gemcitabines differential radiosensitising effect in related bladder cancer cell lines
title_full_unstemmed An evaluation of gemcitabines differential radiosensitising effect in related bladder cancer cell lines
title_short An evaluation of gemcitabines differential radiosensitising effect in related bladder cancer cell lines
title_sort evaluation of gemcitabines differential radiosensitising effect in related bladder cancer cell lines
topic Experimental Therapeutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409540/
https://www.ncbi.nlm.nih.gov/pubmed/14735206
http://dx.doi.org/10.1038/sj.bjc.6601538
work_keys_str_mv AT sangarvk anevaluationofgemcitabinesdifferentialradiosensitisingeffectinrelatedbladdercancercelllines
AT cowanr anevaluationofgemcitabinesdifferentialradiosensitisingeffectinrelatedbladdercancercelllines
AT margisongp anevaluationofgemcitabinesdifferentialradiosensitisingeffectinrelatedbladdercancercelllines
AT hendryjh anevaluationofgemcitabinesdifferentialradiosensitisingeffectinrelatedbladdercancercelllines
AT clarkenw anevaluationofgemcitabinesdifferentialradiosensitisingeffectinrelatedbladdercancercelllines
AT sangarvk evaluationofgemcitabinesdifferentialradiosensitisingeffectinrelatedbladdercancercelllines
AT cowanr evaluationofgemcitabinesdifferentialradiosensitisingeffectinrelatedbladdercancercelllines
AT margisongp evaluationofgemcitabinesdifferentialradiosensitisingeffectinrelatedbladdercancercelllines
AT hendryjh evaluationofgemcitabinesdifferentialradiosensitisingeffectinrelatedbladdercancercelllines
AT clarkenw evaluationofgemcitabinesdifferentialradiosensitisingeffectinrelatedbladdercancercelllines

Ejemplares similares